Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | STAT6 | P42226 | 1/20 | 0.51 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30002373 | 0.99 | ACE (0.53) | ACEF2STAT6C5AR1OPRK1 | |
| SCHEMBL5969907 | 0.93 | F2 (0.52) | ACEF2STAT6C5AR1OPRK1 | |
| SCHEMBL2815390 | 0.90 | F2 (0.49) | ACEF2STAT6C5AR1OPRK1 | |
| SCHEMBL8953791 | 0.89 | C5AR1 (0.52) | ACEF2C5AR1APLNR | |
| SCHEMBL10622567 | 0.89 | C5AR1 (0.54) | F2C5AR1APLNR | |
| SCHEMBL8953877 | 0.88 | C5AR1 (0.55) | F2C5AR1APLNR | |
| SCHEMBL8953840 | 0.87 | C5AR1 (0.52) | ACEF2C5AR1APLNR | |
| SCHEMBL32691458 | 0.85 | SLC6A2 (0.61) | F2C5AR1OPRM1 | |
| SCHEMBL30617831 | 0.85 | F2 (0.58) | F2C5AR1OPRM1APLNR | |
| SCHEMBL31127558 | 0.84 | F2 (0.60) | ACEF2C5AR1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | PROCYTE CORPORATION (US) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052287-A1 | Polyethylene glycol - peptide copper complexes and compositions and methods related thereto | NGLY1, CUTA, TFRC | ACE 2805/4885F2 1072/4885STAT6 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.